Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Waltham, Massachusetts–based Skyhawk Therapeuticshas been collecting collaborations with larger companies in spades since ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...

Janux Therapeutics Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company that develops immunotherapies based on ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the ...

EdiMembre has spun off from Merck Group to commercialise its edible membrane tech for future foods, starting with whole-cut ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline. Click here to read more ...

New Jersey officials are eyeing several efforts, including a massive $500 million incentive program meant to entice more ...